Why the study?
Some foot-and-mouth disease viruses are difficult to adapt to cell culture, slowing manufacturing, reducing vaccine yield, and risking antigenic changes.
Developing recombinant BHK-21 cells that stably express the αvβ6 receptor improves foot-and-mouth disease virus yields without requiring cell culture adaptation, offering a promising approach for vaccine production.
Answers are grounded in this paper and cite their sources.
May enhance FMD vaccine yields via engineered cells; leaves open scalability and in vivo validation.
Foot-and-mouth disease (FMD) is endemic in large parts of sub-Saharan Africa, Asia and South America, where outbreaks in cloven-hooved livestock threaten food security and have severe economic impacts. Vaccination in endemic regions remains the most effective control strategy. Current FMD vaccines are produced from chemically inactivated foot-and-mouth disease virus (FMDV) grown in suspension cultures of baby hamster kidney 21 cells (BHK-21). Strain diversity means vaccines produced from one subtype may not fully protect against circulating disparate subtypes, necessitating the development of new vaccine strains that "antigenically match". However, some viruses have proven difficult to adapt to cell culture, slowing the manufacturing process, reducing vaccine yield and limiting the availability of effective vaccines, as well as potentiating the selection of undesired antigenic changes. To circumvent the need to cell culture adapt FMDV, we have used a systematic approach to develop recombinant suspension BHK-21 that stably express the key FMDV receptor integrin αvβ6. We show that αvβ6 expression is retained at consistently high levels as a mixed cell population and as a clonal cell line. Following exposure to field strains of FMDV, these recombinant BHK-21 facilitated higher virus yields compared to both parental and control BHK-21, whilst demonstrating comparable growth kinetics. The presented data supports the application of these recombinant αvβ6-expressing BHK-21 in future FMD vaccine production.
No takes yet. Share an insight, caveat, or question.
Harvey et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: